Skip to main content
. 2017 Nov 7;8:802. doi: 10.3389/fphar.2017.00802

FIGURE 4.

FIGURE 4

AD0157 causes early and late apoptosis and cleavage of lamin-A and PARP in human myeloid leukemia cells. (A) Representative examples of flow cytometry dot blots for untreated and AD0157-treated leukemia cells. Q1: 7AAD+/PE-Annexin V- (necrotic cells), Q2: 7AAD+/PE-Annexin V+ (late apoptotic cells), Q3: 7AAD -/PE-Annexin V- (viable cells) and Q4: 7AAD-/PE-Annexin V+ (early apoptotic cells). HL60, U937 and KU812F cells were incubated with AD0157 at the indicated concentrations for 14 h and assessed by 7AAD/PE-Annexin V stainings and flow cytometry studies. (B) Quantification of the different populations (necrotic, late and early apoptotic and viable leukemic cells). Values are expressed as means ± SD of three independent experiments. ∗p < 0.05 and #p < 0.005 versus control. (C) Western blots of cleaved lamin-A, PARP and cleaved PARP in HL60, U937 and KU812F control cells and treated for 14 h with the indicated concentrations of AD0157. (D) Quantification by densitometry of Western blot bands. Results are expressed as the average relative protein level percentage ± SD of three independent experiments. The percentage obtained with the higher dose of compound is considered the 100%. #p < 0.005 and ∗∗p < 0.001 versus control.